{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06133114",
            "orgStudyIdInfo": {
                "id": "STUDY-22-01296"
            },
            "organization": {
                "fullName": "Icahn School of Medicine at Mount Sinai",
                "class": "OTHER"
            },
            "briefTitle": "Psychopharmacological Treatment of Emotional Distress",
            "officialTitle": "Psychopharmacological Treatment of Emotional Distress: A Randomized Controlled Trial",
            "therapeuticArea": [
                "Rare Diseases",
                "Other"
            ],
            "study": "psychopharmacological-treatment-of-emotional-distress"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-03-13",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-10",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-10",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-11-10",
            "studyFirstSubmitQcDate": "2023-11-10",
            "studyFirstPostDateStruct": {
                "date": "2023-11-15",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-06",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-07",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Igor Galynker",
                "investigatorTitle": "Clinical Professor",
                "investigatorAffiliation": "Icahn School of Medicine at Mount Sinai"
            },
            "leadSponsor": {
                "name": "Icahn School of Medicine at Mount Sinai",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is an inpatient four-arm randomized control trial comparing single drug clonazepam (S arm), a two-drug combination clonazepam/olanzapine (D arm), and a three-drug combination clonazepam/olanzapine/buprenorphine (T arm) with treatment as usual (TAU arm) in the treatment of emotional distress, specifically the Suicide Crisis Syndrome (SCS). All participants in experimental arms receive 2-day pulse treatments targeting four out of five of the acute emotional distress symptoms. The primary outcome measure is SCS at discharge and one-month follow-up. The secondary outcome measures include questions about suicidal behaviors associated with emotional distress at a one-month follow-up."
        },
        "conditionsModule": {
            "conditions": [
                "Suicide Crisis Syndrome",
                "Psychological Distress"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE4"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 80,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "S arm: Single drug clonazepam",
                    "type": "EXPERIMENTAL",
                    "description": "Single drug clonazepam: 1 mg a day (0.5 mg twice a day) with Treatment As Usual (TAU)",
                    "interventionNames": [
                        "Drug: Clonazepam"
                    ]
                },
                {
                    "label": "D arm: Two-drug combination clonazepam/olanzapine",
                    "type": "EXPERIMENTAL",
                    "description": "Two-drug combination clonazepam/olanzapine: 1 mg a day (0.5 mg twice a day) of Clonazepam plus 2.5 mg a day of Olanzapine with Treatment As Usual (TAU)",
                    "interventionNames": [
                        "Drug: Clonazepam",
                        "Drug: Olanzapine"
                    ]
                },
                {
                    "label": "T arm: Three-drug combination clonazepam/olanzapine/buprenorphine",
                    "type": "EXPERIMENTAL",
                    "description": "Three-drug combination clonazepam/olanzapine/buprenorphine: 1 mg a day (0.5 mg twice a day) of Clonazepam plus 2.5 mg a day of Olanzapine plus 2mg a day of Buprenorphine with Treatment As Usual (TAU)",
                    "interventionNames": [
                        "Drug: Clonazepam",
                        "Drug: Olanzapine",
                        "Drug: Buprenorphine"
                    ]
                },
                {
                    "label": "Control Group",
                    "type": "NO_INTERVENTION",
                    "description": "Participants that will not receive an intervention."
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Clonazepam",
                    "description": "0.5 mg twice a day (1 mg a day)",
                    "armGroupLabels": [
                        "D arm: Two-drug combination clonazepam/olanzapine",
                        "S arm: Single drug clonazepam",
                        "T arm: Three-drug combination clonazepam/olanzapine/buprenorphine"
                    ],
                    "otherNames": [
                        "TAU"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Olanzapine",
                    "description": "2.5 mg once a day of Olanzapine",
                    "armGroupLabels": [
                        "D arm: Two-drug combination clonazepam/olanzapine",
                        "T arm: Three-drug combination clonazepam/olanzapine/buprenorphine"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Buprenorphine",
                    "description": "2 mg once a day of Buprenorphine",
                    "armGroupLabels": [
                        "T arm: Three-drug combination clonazepam/olanzapine/buprenorphine"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Suicide Crisis Syndrome-Checklist (SCS-C)",
                    "description": "The SCS-C is a clinician rated measure assessing clinicians' assessment of the presence and intensity of the Suicide Crisis Syndrome among their patients. The SCS-C includes 13 dichotomous items reflecting the presence or absence of the SCS symptoms. The SCS-C also assesses the presence of the five SCS criteria (entrapment, affective disturbances, loss of cognitive control, hyperarousal and social withdrawal). The first item is a clinician rating of entrapment (SCS criterion A), rated as yes or no. The second item assesses the 4 domains of SCS criterion B: affective disturbance, loss of cognitive control, hyperarousal, and social withdrawal.\n\nThis item is rated yes if the patient exhibits 1 of the domains. A final rating is recorded as positive if both criteria A and B are rated as yes. A positive rating in the final rating reflects a positive SCS diagnosis.",
                    "timeFrame": "up to 1 month follow up after discharge"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Suicide Crisis Inventory-Short Form (SCI-SF) for Severity",
                    "description": "The SCI-SF is an 8-item version of the original 49-item Suicide Crisis Inventory that assesses the severity of different cognitive and affective states theorized in the SCS. Patients rate how they feel on a 5-point scale ranging from 0 (not at all) to 4 (extremely), with higher scores indicating more severe symptoms.",
                    "timeFrame": "up to 1 month follow up after discharge"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Patient admitted to an inpatient unit and ruled in for SCS diagnosis using SCS-C\n* Willing to stay in the hospital voluntarily, if medically necessary, for at least 4 days after enrolling in the study.\n* Patient admitted to an inpatient unit as a result of a recent (i.e., past-month) suicide attempt, as defined by the C-SSRS (Columbia Suicide Rating Scale).\n* Admitted to an inpatient unit in the last 36 hrs.\n* Able to understand the nature and the substance of the consent form.\n* Currently domiciled.\n* Able and willing to provide verifiable contact information for follow-up.\n\nExclusion Criteria:\n\n* Intellectual disability, cognitive impairment, or linguistic limitation precluding understanding of the consent or research questions.\n* Past adverse reactions to clonazepam, olanzapine, or buprenorphine\n* Past history of opiate or benzodiazepine use d/o in the last 2 years\n* On agonist therapy for opiate addiction\n* Ongoing treatment with clonazepam or olanzapine.\n* Significant medical or neurological disease or possible delirium that might interfere with study participation or capacity to provide informed consent.\n* Receiving involuntary treatment in psychiatric unit\n* Clinical suspicion of malingering by a CP.\n* Undomiciled.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Igor Galynker, MD,PhD",
                    "role": "CONTACT",
                    "phone": "212 420 4535",
                    "email": "igor.galynker@mountsinai.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Igor Galynker, MD,PhD",
                    "affiliation": "Icahn School of Medicine at Mount Sinai",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Icahn School of Medicine at Mount Sinai",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10029",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Martina Sobrero, MD",
                            "role": "CONTACT",
                            "email": "martina.sobrero@mssm.edu"
                        },
                        {
                            "name": "Rawad El Hayek, MD",
                            "role": "CONTACT",
                            "email": "rawad.elhayek@mssm.edu"
                        },
                        {
                            "name": "Igor Galynker",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO",
            "description": "No individual participant data will be shared. Results will be published by the investigator in individual journals."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000013405",
                    "term": "Suicide"
                }
            ],
            "ancestors": [
                {
                    "id": "D000016728",
                    "term": "Self-Injurious Behavior"
                },
                {
                    "id": "D000001526",
                    "term": "Behavioral Symptoms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M16355",
                    "name": "Syndrome",
                    "relevance": "LOW"
                },
                {
                    "id": "M16191",
                    "name": "Suicide",
                    "asFound": "Suicide",
                    "relevance": "HIGH"
                },
                {
                    "id": "M19089",
                    "name": "Self-Injurious Behavior",
                    "relevance": "LOW"
                },
                {
                    "id": "M4818",
                    "name": "Behavioral Symptoms",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000002047",
                    "term": "Buprenorphine"
                },
                {
                    "id": "D000002998",
                    "term": "Clonazepam"
                },
                {
                    "id": "D000077152",
                    "term": "Olanzapine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000701",
                    "term": "Analgesics, Opioid"
                },
                {
                    "id": "D000009294",
                    "term": "Narcotics"
                },
                {
                    "id": "D000002492",
                    "term": "Central Nervous System Depressants"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000000700",
                    "term": "Analgesics"
                },
                {
                    "id": "D000018689",
                    "term": "Sensory System Agents"
                },
                {
                    "id": "D000018373",
                    "term": "Peripheral Nervous System Agents"
                },
                {
                    "id": "D000009292",
                    "term": "Narcotic Antagonists"
                },
                {
                    "id": "D000000932",
                    "term": "Antiemetics"
                },
                {
                    "id": "D000001337",
                    "term": "Autonomic Agents"
                },
                {
                    "id": "D000005765",
                    "term": "Gastrointestinal Agents"
                },
                {
                    "id": "D000014150",
                    "term": "Antipsychotic Agents"
                },
                {
                    "id": "D000014149",
                    "term": "Tranquilizing Agents"
                },
                {
                    "id": "D000011619",
                    "term": "Psychotropic Drugs"
                },
                {
                    "id": "D000017367",
                    "term": "Selective Serotonin Reuptake Inhibitors"
                },
                {
                    "id": "D000014179",
                    "term": "Neurotransmitter Uptake Inhibitors"
                },
                {
                    "id": "D000049990",
                    "term": "Membrane Transport Modulators"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000018377",
                    "term": "Neurotransmitter Agents"
                },
                {
                    "id": "D000018490",
                    "term": "Serotonin Agents"
                },
                {
                    "id": "D000000927",
                    "term": "Anticonvulsants"
                },
                {
                    "id": "D000018757",
                    "term": "GABA Modulators"
                },
                {
                    "id": "D000018682",
                    "term": "GABA Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M1675",
                    "name": "Olanzapine",
                    "asFound": "Field",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5317",
                    "name": "Buprenorphine",
                    "asFound": "Attention",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6230",
                    "name": "Clonazepam",
                    "asFound": "BI 10773",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4033",
                    "name": "Analgesics, Opioid",
                    "relevance": "LOW"
                },
                {
                    "id": "M4032",
                    "name": "Analgesics",
                    "relevance": "LOW"
                },
                {
                    "id": "M12245",
                    "name": "Narcotics",
                    "relevance": "LOW"
                },
                {
                    "id": "M12243",
                    "name": "Narcotic Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M4251",
                    "name": "Antiemetics",
                    "relevance": "LOW"
                },
                {
                    "id": "M8881",
                    "name": "Gastrointestinal Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M16904",
                    "name": "Antipsychotic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M14474",
                    "name": "Psychotropic Drugs",
                    "relevance": "LOW"
                },
                {
                    "id": "M15512",
                    "name": "Serotonin",
                    "relevance": "LOW"
                },
                {
                    "id": "M19649",
                    "name": "Selective Serotonin Reuptake Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20504",
                    "name": "Neurotransmitter Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4246",
                    "name": "Anticonvulsants",
                    "relevance": "LOW"
                },
                {
                    "id": "M20827",
                    "name": "GABA Modulators",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "AnEm",
                    "name": "Antiemetics"
                },
                {
                    "abbrev": "CNSDep",
                    "name": "Central Nervous System Depressants"
                },
                {
                    "abbrev": "PsychDr",
                    "name": "Psychotropic Drugs"
                },
                {
                    "abbrev": "Gast",
                    "name": "Gastrointestinal Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Analg",
                    "name": "Analgesics"
                },
                {
                    "abbrev": "NarcAntag",
                    "name": "Narcotic Antagonists"
                },
                {
                    "abbrev": "AntiConv",
                    "name": "Anticonvulsants"
                }
            ]
        }
    },
    "hasResults": false
}